Placenta in Health and Disease - Grants, Research funding
We are grateful to the following Grant Agencies for funding our research:
|
Period |
Grant title |
Source |
| 2023-2025 | Cannabis use in pregnancy; effects on endocrine and immune functions of the placenta (GACR 23-07094S) | GACR |
|
2022-2025 |
National Institute for Neurological Research |
EXCELES |
|
2022-2025 |
Effects of gestational diabetes on placental inflammasome |
AZV |
|
2022-2024 |
Impact of maternal immune activation on serotonergic system in the fetoplacental unit and fetal, juvenile and adult neurodevelopment (GACR 22-08045S) |
GACR |
|
2022-2024 |
Use of cannabis in pregnancy; effect on placental functions |
GAUK |
|
2021-2023 |
Pregnancy disorders; effect on fetal development and programming |
START |
|
2021-2023 |
Pharmacotherapy in pregnancy; effect on monoamine homeostasis in the placenta |
GAUK |
| 2019-2022 |
Engineering a novel cell-based model for assessing materno-fetal drug transfer during pregnancy (OC-2019-019) |
Swiss 3R Competence Centre |
|
2020-2024 |
Placental tryptophan metabolism linking maternal inflammation and foetal neurodevelopmental disorders (AZV NU20-01-00264) |
AZV |
|
2020-2023 |
Antidepressants in pregnancy; effect on placental transport and metabolism of serotonin (GACR 20-13017S) |
GACR |
|
2019-2021 |
Pharmacotherapy in pregnancy; effect on monoamine homeostasis in the placenta |
GAUK |
|
2017-2019 |
In vitro, in situ and ex vivo study of interactions of novel antiviral agents with drug transporters; effect on their passage across the placenta (GACR 17-16169S) |
GACR |
|
2016-2018 |
Interactions of protein kinase inhibitors with drug transporters and biotransformation enzymes; role in overcoming resistance in anticancer therapy (GACR 16-26849S) |
GACR |
|
2012-2016 |
Transplacental pharmacokinetics of antiretroviral drugs; interactions with drug efflux transporters (P303/12/0850) |
GACR |
|
2012-2014 |
Study of interaction of cyclin-dependent kinase inhibitors with ABCB1 drug efflux transporter (700912 C 2012) |
GAUK |
|
2012-2014 |
Study of transplacental pharmacokinetics of antiretroviral drugs emtricitabine, tenofovir and tenofovir disoproxil fumarate; interactions with drug-efflux transporters (695912 C 2012) |
GAUK |
|
2010-2012 |
Localization and function of Organic Cation Transporter 3 (OTC3) in the Rat Placenta (114510 C 2009) |
GAUK |
|
2009-2011 |
Interactions of Breast Cancer Resistance Protein (BCRP/ABCG2) and Purine Cyclin-dependent Kinase Inhibitors In Vitro and In Situ (114909 C 2009) |
GAUK |
|
2007-2009 |
Role of efflux transporters in the placenta for fetus protection and detoxication (119007 C 2007) |
GAUK |
|
2007-2009 |
Regulation mechanisms of drug elimination during hepatic injury (116807 C 2007) |
GAUK |
|
2006-2008 |
Expression and function of BCRP in the placenta at different stages of gestation (103/2006 C) |
GAUK |
|
2006-2007 |
Expression and function of 11β-HSD2 in the placenta in vitro and in vivo (102/2006 C) |
GAUK |
|
2005-2008 |
In-vitro study of molecular-genetic cause of cell resistance against selected drugs (1A8696-4/2005) |
IGA |
|
2005-2007 |
Cytochrome P450 3A4 and multidrug resistance proteins MDR1 and MRP2 as main cause of drug interaction during elimination of drugs from organism (092/2005/C/LFHK) |
GAUK |
|
2005-2006 |
Study of interactions of antiepileptic drugs with efflux transporters (BCRP, MRP2 and P-glycoprotein) in vitro (94/2005/C/FaF) |
GAUK |
|
2005 |
RNA interference in transepithelial transport studies (753/2005) |
FRVŠ |
|
2004-2006 |
Investigation of drug efflux transporters using RNA interference and transfected cell lines (151/2004/C/FaF) |
GAUK |
|
2004 |
Building laboratories of molecular pharmacology (908/2004) |
FRVŠ |
|
2004 |
Visualization of placental membrane transporters using fluorescence microscopy (38p17) |
AKTION |